Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.
Pérez de Isla L, Díaz-Díaz JL, Romero MJ, Muñiz-Grijalvo O, Mediavilla JD, Argüeso R, Sánchez Muñoz-Torrero JF, Rubio P, Álvarez-Baños P, Ponte P, Mañas D, Suárez Gutierrez L, Cepeda JM, Casañas M, Fuentes F, Guijarro C, Ángel Barba M, Saltijeral Cerezo A, Padró T, Mata P; SAFEHEART Study Group. Pérez de Isla L, et al. Among authors: cepeda jm. Circulation. 2023 May 9;147(19):1436-1443. doi: 10.1161/CIRCULATIONAHA.122.062557. Epub 2023 Apr 3. Circulation. 2023. PMID: 37009731 Free PMC article.
Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study.
Fuentes F, Alcala-Diaz JF, Watts GF, Alonso R, Muñiz O, Díaz-Díaz JL, Mata N, Sanchez Muñoz-Torrero JF, Brea Á, Galiana J, Figueras R, Aguado R, Piedecausa M, Cepeda JM, Vidal JI, Rodríguez-Cantalejo F, López-Miranda J, Mata P; SAFEHEART Investigators. Fuentes F, et al. Among authors: cepeda jm. Int J Cardiol. 2015 Dec 15;201:79-84. doi: 10.1016/j.ijcard.2015.07.107. Epub 2015 Aug 5. Int J Cardiol. 2015. PMID: 26296047
Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study).
Pérez de Isla L, Alonso R, Mata N, Fernández-Pérez C, Muñiz O, Díaz-Díaz JL, Saltijeral A, Fuentes-Jiménez F, de Andrés R, Zambón D, Piedecausa M, Cepeda JM, Mauri M, Galiana J, Brea Á, Sanchez Muñoz-Torrero JF, Padró T, Argueso R, Miramontes-González JP, Badimón L, Santos RD, Watts GF, Mata P. Pérez de Isla L, et al. Among authors: cepeda jm. Circulation. 2017 May 30;135(22):2133-2144. doi: 10.1161/CIRCULATIONAHA.116.024541. Epub 2017 Mar 8. Circulation. 2017. PMID: 28275165 Free article.
Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study.
Pérez de Isla L, Arroyo-Olivares R, Muñiz-Grijalvo O, Diaz-Díaz JL, Zambón D, Fuentes F, Sánchez Muñoz-Torrero JF, Mediavilla JD, González-Estrada A, Miramontes-González JP, de Andrés R, Mauri M, Mosquera D, Cepeda JM, Suárez L, Barba-Romero MÁ, Argüeso R, Álvarez-Baños P, Michán A, Romero-Jiménez MJ, García-Cruces J, Padró T, Alonso R, Mata P. Pérez de Isla L, et al. Among authors: cepeda jm. J Clin Lipidol. 2019 Nov-Dec;13(6):989-996. doi: 10.1016/j.jacl.2019.10.005. Epub 2019 Oct 11. J Clin Lipidol. 2019. PMID: 31706904 Free article.
Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry.
Pérez de Isla L, Arroyo-Olivares R, Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, Fuentes F, Mata N, Piedecausa M, Mañas MD, Sánchez Muñoz-Torrero JF, Miramontes-González JP, de Andrés R, Mauri M, Aguado R, Brea Á, Cepeda JM, Vidal-Pardo JI, Martínez-Faedo C, Barba MÁ, Argüeso R, Ruiz-Pérez E, Michán A, Arrieta F, Riestra Fernández M, Pérez L, Pinilla JM, Díaz-Soto G, Pintó X, Padró T, Badimón L, Mata P; SAFEHEART researchers. Pérez de Isla L, et al. Among authors: cepeda jm. Rev Esp Cardiol (Engl Ed). 2020 Oct;73(10):828-834. doi: 10.1016/j.rec.2019.10.028. Epub 2020 Mar 20. Rev Esp Cardiol (Engl Ed). 2020. PMID: 32201274 English, Spanish.
Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience.
Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, de Andrés R, Arroyo-Olivares R, Fuentes-Jimenez F, Muñoz-Torrero JS, Cepeda J, Aguado R, Alvarez-Baños P, Casañas M, Dieguez M, Mañas MD, Rubio P, Argueso R, Arrieta F, Gonzalez-Bustos P, Perez-Isla L, Mata P; SAFEHEART investigators. Alonso R, et al. J Clin Lipidol. 2021 Jul-Aug;15(4):584-592. doi: 10.1016/j.jacl.2021.04.011. Epub 2021 May 7. J Clin Lipidol. 2021. PMID: 34052174
The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia.
Gallo A, Pérez de Isla L, Charrière S, Vimont A, Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, Moulin P, Bruckert E, Mata P, Béliard S; REFERCHOL and SAFEHEART Investigators. Gallo A, et al. JACC Cardiovasc Imaging. 2021 Dec;14(12):2414-2424. doi: 10.1016/j.jcmg.2021.06.011. Epub 2021 Jul 14. JACC Cardiovasc Imaging. 2021. PMID: 34274263 Free article.
Rivaroxaban: searching the integral vascular protection.
Barrios V, Almendro-Delia M, Facila L, Garcia-Moll X, Mazón P, Camafort M, Cepeda JM, Mediavilla Garcia JD, Pose Reino A, Suarez Fernandez C. Barrios V, et al. Among authors: cepeda jm. Expert Rev Clin Pharmacol. 2018 Jul;11(7):719-728. doi: 10.1080/17512433.2018.1495559. Epub 2018 Jul 18. Expert Rev Clin Pharmacol. 2018. PMID: 29965791 Review.
42 results